Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study (PEARL): A Prospective, Double-Blind, Placebo-Controlled Trial for Rapamycin in Healthy Individuals Assessing Safety and Efficacy in Reducing Aging Effects

NCT04488601 is registered in ClinicalTrials.gov with AgelessRx as lead sponsor.

NCT NCT04488601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04488601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study (PEARL): A Prospective, Double-Blind, Placebo-Controlled Trial for Rapamycin in Healthy Individuals Assessing Safety and Efficacy in Reducing Aging Effects
Lead sponsor
AgelessRx
Phase
Phase 2
Overall status
Completed
Start date
January 1, 2020
Completion date
December 30, 2023
Enrollment
129 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aging